smpСкорая медицинская помощьEMERGENCY MEDICAL CARE2072-6716Northwest State Medical University named after II Mechnikov10.24884/2072-6716-2023-24-1-4-12smp-610Research ArticleСТАТЬИARTICLESЛечение и профилактика мерцательной аритмии: новые подходы и нерешенные вопросыTreatment and prevention of atrial fibrillation and flutter: new approaches and unsolved questionsШальневВ. И.ShalnevV. I.

Шальнев Владимир Ильич — доктор медицинских наук, профессор кафедры скорой медицинской помощи, 

191015, Санкт-­Петербург, Кирочная ул., д. 41

Vladimir I. Shalnev,

St. Petersburg

VISSZGMU@yandex.ruСеверо-Западный государственный медицинский университет им. И. И. МечниковаРоссияNorth-Western State Medical University named after I. I. MechnikovRussian Federation202317032023241412Copyright © Шальнев В.И., 20232023Шальнев В.И.Shalnev V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://smp.spb.ru/jour/article/view/610

В статье изложены современные представления об этиологии, патогенезе, подходах к терапии и профилактике фибрилляции и трепетания предсердий (ФП и ТП). Освещаются новые международные и российские клинические рекомендации по лечению и профилактике фибрилляции предсердий. Обсуждаются новые антиаритмические препараты, представленные в этих рекомендациях. Анализируется собственный опыт по изучению эффективности антиаритмических средств IC класса (пропафенонa) при купировании пароксизмов ФП на догоспитальном этапе. 

The article highlights the modern understanding of etiology, epidemiology and pathogenesis of atrial fibrillation and flutter and their global burden as the most frequent form of supraventricular sustained tachyarrhythmia. The recent international and Russian national clinical guidelines on the treatment and prevention of atrial fibrillation are briefly discussed. The new antiarrhythmic drugs, presented in recent guidelines are also highlighted. The authors analyze their own experience in the treatment of paroxysmal atrial fibrillation with IC class drugs (propafenone) at the prehospital stage. 

мерцательная аритмияфибрилляция и трепетание предсердийтахиаритмииантиаритмические средстваatrial fibrillation and fluttertachyarrhythmiaantiarrhythmic drugsReferencesФибрилляция и трепетание предсердий. Российские клинические рекомендации 2020. Доступно на сайте РКО: www.scardio.ruAtrial fibrillation and flutter. Clinical guidelines. Russian Society of cardiology, 2020. Available on the website RKO: www.scardio.ru (In Russ.).Hindricks G., Potpara P., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation // Eur. Heart J. 2020. Vol. 00. Р. 1–126. doi:10.1093/eurheartj/ehaa612Hindricks G., Potpara P., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation // Eur. Heart J. 2020. Vol. 00. Р. 1–126. doi:10.1093/eurheartj/ehaa612Кушаковский М.С., Гришкин Ю.Н. Аритмии сердца. СПб.: Фолиант, 2020. 720 с.Kushakovsky M.S., Grishkin Yu. N. Heart arrhythmias. St. Petersburg: Рublishing house Foliant, 2020, 720 p. (In Russ.).Плавунов Н.Ф., Гапонова Н.И., Кадышев В.А. и др. Клинико-статистический анализ пациентов с фибрилляцией предсердий // Архивъ внутренней медицины. 2018. Т. 8, № 5. С. 389–393. doi: 10.20514/2226-6704-2018-8-5-389-393.Plavunov N.F., Gaponova N.I., Kadishev V. A et al. Clinical and statistical analysis of patients with atrial fibrillation. Archive of internal medicine, 2018, Vol. 8, No. 5, pp. 389–393 (In Russ.). doi: 10.20514/2226-6704-2018-8-5-389-393.Staerk L., Sherer J.A., Ko D. et. al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes // Circulation Res. 2017. Vol. 120. P. 1501–1517.Staerk L., Sherer J.A., Ko D. et. al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes // Circulation Res. 2017. Vol. 120. P. 1501–1517.Schnabel R.B., Yin X., Gona P. et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study // Lancet. 2015. Vol. 386. P. 154–162.Schnabel R.B., Yin X., Gona P. et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study // Lancet. 2015. Vol. 386. P. 154–162.Heeringa J., van der Kuip D.A., Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study // Eur. Heart J. 2006. Vol. 27. P. 949–953. doi: 10.1093/eurheartj/ehi825.Heeringa J., van der Kuip D.A., Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study // Eur. Heart J. 2006. Vol. 27. P. 949–953. doi: 10.1093/eurheartj/ehi825.Staerk L., Wang B., Preis S.R. et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study // Brit. Med. J. 2018. Vol. 361. P. 1453–1460.Staerk L., Wang B., Preis S.R. et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study // Brit. Med. J. 2018. Vol. 361. P. 1453–1460.Dewland T.A., Olgin J.E., Vittinghoff E. et al. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites // Circulation. 2013. Vol. 128. P. 2470–2477.Dewland T.A., Olgin J.E., Vittinghoff E. et al. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites // Circulation. 2013. Vol. 128. P. 2470–2477.Chao T.F., Liu C.J., Tuan T.C. et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF Cohort Study // Chest. 2018. Vol. 153. P. 453–466.Chao T.F., Liu C.J., Tuan T.C. et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF Cohort Study // Chest. 2018. Vol. 153. P. 453–466.Mou L., Norby F.L., Chen L.Y. et al. Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study // Circulation Arrhythm. Electrophysiol. 2018. Vol. 11. e006350.Mou L., Norby F.L., Chen L.Y. et al. Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study // Circulation Arrhythm. Electrophysiol. 2018. Vol. 11. e006350.Ko D., Rahman F., Schnabel R. et al. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis // Nat. Rev. Cardiol. 2016. Vol. 13. P. 321–332.Ko D., Rahman F., Schnabel R. et al. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis // Nat. Rev. Cardiol. 2016. Vol. 13. P. 321–332.Alonso A. Racial differences in atrial fibrillation-related cardiovascular disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study // JAMA Cardiol. 2016. Vol. 1. P. 433–441. doi: 0.1001/jamacardio.2016.1025Alonso A. Racial differences in atrial fibrillation-related cardiovascular disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study // JAMA Cardiol. 2016. Vol. 1. P. 433–441. doi: 0.1001/jamacardio.2016.1025Мареев Ю.В., Поляков Д.С., Виноградова Н.Г. и др. ЭПОХА: Эпидемиология фибрилляции предсердий в репрезентативной выборке Европейской части Российской Федерации // Кардиология. 2022. Т. 62, № 4. С. 12–19.Mareev Yu.V., Polyakov D.S., Vinogradova N.G. et al. EPOCHA: Epidemiology of atrial fibrillation in the representative cohort of European part of Russian Federation. Cardiology, 2022. Vol. 62, No. 4, pp. 12–19 (In Russ.).Шапкина М.Ю., Маздорова Е.В., Авдеева Е.М. и др. Динамика частоты фибрилляции предсердий в российской популяционной выборке за 13 лет наблюдения // Кардиоваскулярная терапия и профилактика. 2022. T. 21, № 8. C. 23–33.Shapkina M.Yu., Mazdorova E.V., Avdeeva E.M. e al. Dynamics of frequency of atrial fibrillation in Russian population sample during 13 years follow-up. Cardiovascular therapy and prevention, 2022. Vol. 21, No. 8, pp. 23–33 (In Russ.).Rosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2008. Vol. 117. P. 25–46.Rosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2008. Vol. 117. P. 25–46.Gunlund A., Kumler T., Bonde A. et. al. Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant — Danish nationwide cohort study // Brit. Med. J. Open. 2019. Vol. 9. e028468. doi: 10.1 136/bmjopen-2018-028468.Gunlund A., Kumler T., Bonde A. et. al. Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant — Danish nationwide cohort study // Brit. Med. J. Open. 2019. Vol. 9. e028468. doi: 10.1 136/bmjopen-2018-028468.Kim M., Johnston S., Dalal M.R. et al. Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States // Circulation. 2011. Vol. 4. P. 313–320.Kim M., Johnston S., Dalal M.R. et al. Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States // Circulation. 2011. Vol. 4. P. 313–320.Potpara T.S., Lip G.H., Dagres N. et al. Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry // Eur. Heart J. Qual. Care Clin. Outcomes. 2021. Vol. 7. P. 229–237. doi: 10.10 93/ehjqcco/qcaa050.Potpara T.S., Lip G.H., Dagres N. et al. Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry // Eur. Heart J. Qual. Care Clin. Outcomes. 2021. Vol. 7. P. 229–237. doi: 10.10 93/ehjqcco/qcaa050.Heidbuchel H., Van Gelder I., Destegh L. et al. ESC and EHRA lead a path towards integrated care for multimorbid atrial fibrillation patients: the Horizon 2020 EHRA-PATHS project // Eur. Heart J. 2022. Vol. 43. P. 1450–1452.Heidbuchel H., Van Gelder I., Destegh L. et al. ESC and EHRA lead a path towards integrated care for multimorbid atrial fibrillation patients: the Horizon 2020 EHRA-PATHS project // Eur. Heart J. 2022. Vol. 43. P. 1450–1452.Haпssaguerre M., Jaпs P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.Haпssaguerre M., Jaпs P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.El-Armouche A., Boknik P., Eschenhagen T. et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation // Circulation. 2006. Vol. 114. P. 670–680.El-Armouche A., Boknik P., Eschenhagen T. et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation // Circulation. 2006. Vol. 114. P. 670–680.Allessie M.A., de Groot N.M., Houben R.P. et al. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation // Circulation Arrhythm. Electrophysiol. 2010. Vol. 3. P. 606–615.Allessie M.A., de Groot N.M., Houben R.P. et al. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation // Circulation Arrhythm. Electrophysiol. 2010. Vol. 3. P. 606–615.Greenberg J.W., Lancaster T., Schuessler R. Postoperative atrial fibrillation following cardiac surgery: a persistent complication // European Journal of Cardio-Thoracic Surgery. 2017. Vol. 52. P. 665–672. doi: 10.1093/ejcts/ezx039.Greenberg J.W., Lancaster T., Schuessler R. Postoperative atrial fibrillation following cardiac surgery: a persistent complication // European Journal of Cardio-Thoracic Surgery. 2017. Vol. 52. P. 665–672. doi: 10.1093/ejcts/ezx039.Halonen J., Järvinen O., Taskinen P., et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial // JAMA. 2007. Vol. 297. P. 1562–1567. doi: 10.1001/jama.297.14.156.Halonen J., Järvinen O., Taskinen P., et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial // JAMA. 2007. Vol. 297. P. 1562–1567. doi: 10.1001/jama.297.14.156.Imazio M., Brucato A., Ferrazzi P. et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the prevention of the postpericardiotomy syndrome (COPPS) atrial fibrillation substudy // Circulation. 2011. Vol. 124. P. 2290–2295.Imazio M., Brucato A., Ferrazzi P. et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the prevention of the postpericardiotomy syndrome (COPPS) atrial fibrillation substudy // Circulation. 2011. Vol. 124. P. 2290–2295.Van Wagoner D.R., Chung M.K. Inflammation, inflammasome activation, and atrial fibrillation // Circulation. 2018. Vol. 138. P. 2243–2246. doi: 10.1161/CIRCULATIONAHA.118.036143.Van Wagoner D.R., Chung M.K. Inflammation, inflammasome activation, and atrial fibrillation // Circulation. 2018. Vol. 138. P. 2243–2246. doi: 10.1161/CIRCULATIONAHA.118.036143.Harada M., Van Vagoner D., Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management // Circulation J. 2015. Vol. 79. P. 495–502.Harada M., Van Vagoner D., Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management // Circulation J. 2015. Vol. 79. P. 495–502.Inacio J.F., da Rosa Mdos S., Shah J. et al. Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: systematic review and network meta-analysis // Resuscitation. 2016. Vol. 100. P. 66–75.Inacio J.F., da Rosa Mdos S., Shah J. et al. Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: systematic review and network meta-analysis // Resuscitation. 2016. Vol. 100. P. 66–75.Шальнев В.И., Соколов Ю.В. Эффективность пропафенона при лечении пароксизмов фибрилляции предсердий на догоспитальном этапе // Материалы 2-й Северо-Западной научной конференции по проблеме внезапной смерти. СПб., 1998. C. 58–59.Shalnev V.I., Sokolov Yu. V. The efficacy of propafenone in the treatment of paroxysmal atrial fibrillation at the prehospital stage. Materials of 2th North-Western scientific conference on the problem of sudden death. St. Petersburg, 1998, pр. 58–59 (In Russ.).Шальнев В.И., Соколов Ю.В. Внутривенное введение пропафенона на догоспитальном этапе — эффективный и безопасный метод купирования пароксизмов фибрилляции предсердий // Материалы Всероссийской научной конференции, посвященной 100-летию акад. А. Л. Мясникова. СПб., 1999. C. 140.Shalnev V.I., Sokolov Yu. V. Intravenous propafenone as an effective and safe way of treatment for paroxysmal atrial fibrillation // Materials of all-Russian scientific conference dedicated to the 100th anniversary of academician A. L. Myasnikov, St. Petersburg, 1999, p. 140 (In Russ.).Шальнев В.И., Мирошниченко А.Г., Соколов Ю.В. Внутривенное введение пропафенона при пароксизмальной форме мерцания предсердий на догоспитальном этапе // Скорая медицинская помощь. 2000. № 4. С. 40– 44.Shalnev V.I., Miroshnichenko A.G., Sokolov Yu. V. Intravenous propafenone for paroxysmal atrial fibrillation at the prehospital stage. Emergency Medical Care, 2000, No. 2, pp. 40–44 (In Russ.).Шальнев В.И., Соколов Ю.В. Внутривенное введение пропафенона на догоспитальном этапе — реальная альтернатива традиционным методам купирования пароксизмов фибрилляции предсердий // Материалы 6-й Всероссийской научной конференции «Кардиостим 2000». СПб., 2000. C. 96–97.Shalnev V.I., Sokolov Yu.V. Intravenous propafenone at the prehospital stage —  the real alternative for traditional way of treatment of paroxysmal atrial fibrillation. Materials of all-Russian 6th scientific conference Cardiostim 2000. St. Petersburg, 2000, pp. 96–97 (In Russ.).Лукьянова И.Ю., Кузнецов А.В., Шальнев В.И. Медикаментозная кардиоверсия при пароксизмальной форме трепетания предсердий на догоспитальном этапе // Скорая медицинская помощь. 2021. Т. 22, № 4. С. 55–59.Loukianova I.Yu., Kuznetsov A.V., Shalnev V.I. Pharmacological cardioversion of paroxysmal atrial flutter at the prehospital stage. Emergency Medical Care, 2021, Vol. 22, No. 4, pp. 55–59 (In Russ.).Duggan S.T., Scott L.J. Intravenous vernacalant: a review of its use in the management of recent-oncet atrial fibrillation // Drugs. 2011. Vol. 71. P. 237–252.Duggan S.T., Scott L.J. Intravenous vernacalant: a review of its use in the management of recent-oncet atrial fibrillation // Drugs. 2011. Vol. 71. P. 237–252.Savelieva I., Graydon R., Camm A.J. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines // Europace. 2014. Vol. 16. P. 162–173.Savelieva I., Graydon R., Camm A.J. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines // Europace. 2014. Vol. 16. P. 162–173.Pratt C.M., Roy D., Torp-Pedersen C. et al. Atrial Arrhythmia Conversion Trial (ACT-III) Investigators // Am. J. Cardiol. 2010. Vol. 106, No. 9. P. 1277–1283.Pratt C.M., Roy D., Torp-Pedersen C. et al. Atrial Arrhythmia Conversion Trial (ACT-III) Investigators // Am. J. Cardiol. 2010. Vol. 106, No. 9. P. 1277–1283.Beatch G.N., Mangal B. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial // BMC Cardiovasc. Disord. 2016. Vol. 16. P. 113–119.Beatch G.N., Mangal B. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial // BMC Cardiovasc. Disord. 2016. Vol. 16. P. 113–119.Camm A.J., Capucci A., Hohnloser S.H. et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation // J. Am. Coll. Cardiol. 2011. Vol. 57. P. 313–321.Camm A.J., Capucci A., Hohnloser S.H. et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation // J. Am. Coll. Cardiol. 2011. Vol. 57. P. 313–321.Pohjantahti-Maaroos H., Hyppola H., Lekkala M. et al. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation // Eur. Heart J. Acute Cardiovasc. Care. 2019. Vol. 8. P. 114–120.Pohjantahti-Maaroos H., Hyppola H., Lekkala M. et al. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation // Eur. Heart J. Acute Cardiovasc. Care. 2019. Vol. 8. P. 114–120.Simon A., Niederdoecl J., Skylluoriotis E. et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department // EP Europace. 2017. Vol. 19. P. 233–240.Simon A., Niederdoecl J., Skylluoriotis E. et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department // EP Europace. 2017. Vol. 19. P. 233–240.Ma W., Guo X., Wang Q. et. al. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation // Journal of Cardiovascular Pharmacology. 2020. Vol. 76. P. 32–41.Ma W., Guo X., Wang Q. et. al. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation // Journal of Cardiovascular Pharmacology. 2020. Vol. 76. P. 32–41.

The authors declare that there are no conflicts of interest present.